Drug patent expiration presents a significant opportunity for the launch of generic medications, which can dramatically alter market dynamics. When a branded drug's patent expires, it opens the door for generic manufacturers to produce and sell bioequivalent versions at a lower cost, leading to increased competition and reduced prices. This not only makes medications more accessible to patients but also creates substantial market opportunities for generic pharmaceutical companies. Strategic planning around patent cliffs allows these companies to capitalize on established demand while healthcare systems benefit from cost savings.
Here are some medicines which patent are expiring soon
Fluoroestradiol F-18
Patent to expire on May 20, 2025. Fluoroestradiol F 18 injection is used together with biopsy to help detect estrogen receptor (ER)-positive lesions in patients with recurrent or metastatic breast cancer (cancer that keeps coming back or has spread to the other parts of the body). It is used in a procedure called positron emission tomography (PET) scan to help your doctor see an image of your breast. This medicine is not used to detect other types of lesion receptors, including human epidermal growth factor receptor 2 (HER2) and progesterone receptor (PR). Fluoroestradiol F 18 is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents, which may be used to find and treat certain diseases or to study the function of the body's organs. The market size was valued at USD 1.4 billion in 2020 and is projected to reach USD 3 billion by 2030
Dehydrated Alcohol - ABLYSINOL
Patent to expire on June 21, 2025, ABLYSINOL is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy. The global industrial alcohol market, which includes Ablysinol, is projected to reach USD 373.35 billion by 2032.
Bremelanotide Acetate - VYLEESI
Patent to expire on June 28, 2025. With five patents and a significant presence globally, this drug's transition to generics will expand treatment options for its users. Vyleesi is commonly used to treat low sex drive (hypoactive sexual desire disorder or HSDD) in certain women before menopause. It is not for people whose low sex drive is caused by medical or mental health problems, relationship problems, or medicines or drug use.
Naltrexone Hydrochloride and Oxycodone Hydrochloride
Patent to expire on July 3, 2025, TROXYCA ER, the combination is used to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment, when other pain medicines did not work well enough or cannot be tolerated. The global Naltrexone HCL market is projected to grow, with a market size of approximately USD 5.31 billion in 2024 and expected to exceed USD 15.32 billion by 2034
Tafenoquine Succinate - KRINTAFEL
Patent expire on July 20, 2025; Tafenoquine succinate is primarily used for the prevention and radical cure of malaria, specifically targeting Plasmodium vivax infections. It is approved by the FDA for malaria prophylaxis in adults and for radical cure of P. vivax malaria in individuals 16 years and older.
Testosterone Undecanoate KYZATREX,
Patents to expire on July 27, 2025; The global testosterone replacement therapy (TRT) market, which includes Kyzatrex (testosterone undecanoate), is projected to grow to USD 2.1 billion in 2025, up from USD 2.04 billion in 2024; This medication is used by men who have low or no testosterone due to certain medical conditions (such as hypogonadism). Testosterone belongs to a class of drugs known as androgens. It helps the body to develop and maintain male sexual characteristics (masculinity), such as a deep voice and body hair.
Fish Oil Triglycerides OMEGAVEN
Patent to expire on July 27, 2025; Omegaven Infusion is a nutritional supplement. It contains omega-3-fatty acids which are powerful antioxidants. Antioxidants prevent damage to the body due to harmful chemicals in our body known as free radicals. This enhances the overall health of an individual. The global omega-3 supplement market, which includes products like OMEGAVEN, was valued at USD 7.68 billion in 2024
Iobenguane 1-131 - AZEDRA
Patent to expire on July 30, 2025. Azedra is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.
Migalastat Hydrochloride - GALAFOLD
Patents to expire on August 10, 2025. GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data
Estradiol Acetate - FEMTRACE
Patent to expire on October 2, 2025; Estradiol acetate (EA), sold under the brand names Femtrace, Femring, and Menoring, is an estrogen medication which is used in hormone therapy for the treatment of menopausal symptoms in women. It is taken by mouth once daily or given as a vaginal ring once every three months.
Rilpivirine Hydrochloride - EDURANT
Patent to expire on October 21, 2025; EDURANT in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients. The global HIV drugs market, which includes rilpivirine hydrochloride (EDURANT), was valued at USD 32.8 billion in 2022 and is projected to reach USD 51.1 billion by 2032.
Gallium Ga-68 PSMA-11
Patent to expire on December 1, 2025; Gallium Ga-68 PSMA-11 is a radioactive imaging agent used with PET scans to help detect prostate cancer and identify potential metastases. It works by binding to PSMA (prostate-specific membrane antigen), a protein found on the surface of prostate cancer cells, and then is detected by the PET scanne
Nepafenac - NEVANAC
Patent to expire on December 2, 2025, Nepafenac, sold under the brand name Nevanac, is a nonsteroidal anti-inflammatory drug (NSAID) used as an eye drop to treat pain and swelling after cataract surgery. It helps reduce inflammation and discomfort by blocking the release of chemicals that cause pain and swelling. Nevanac is available in a 5ml bottle of ophthalmic suspension. Global Nepafenac market size 2025 is USD 1.27 billion whereas according out published study it will reach to USD 2.43 Billion by 2033.
Abaloparatide - TYMLOS
Patent to expire on December 19, 2025; Abaloparatide (Tymlos) is a liquid medicine that has been approved for treatment of osteoporosis in postmenopausal women and in men. It contains a parathyroid hormone protein. While continuously high parathyroid hormone levels cause bone loss, tiny daily doses of parathyroid hormone increase bone formation and density.
Tapentadol Hydrochloride - NUCYNTA ER
Patent to expire on December 27, 2025; Tapentadol ER (Nucynta Extended-Release) is indicated for the management of patients with pain severe enough to require daily, continuous, long-term opioid treatment, and that is opioid responsive, and for which alternative treatment options are inadequate.
Albuterol Sulfate and Budesonide - AIRSUPRA
Patent to expire on January 10, 2026; AIRSUPRA is the only asthma rescue inhaler FDA-approved to treat symptoms and help prevent asthma attacks; The market for AIRSUPRA (albuterol/budesonide) is a component of the larger asthma therapeutics market. While specific AIRSUPRA market size data isn't readily available, the global asthma therapeutics market was valued at USD 18.83 billion in 2024 and is projected to reach USD 22.1 billion by 2033.
The future of pharma innovation is poised to be driven by advances in precision medicine, artificial intelligence, and biotechnology. As the industry shifts toward more personalized and targeted therapies, innovations such as gene editing, mRNA platforms, and cell-based treatments are transforming the drug development landscape. AI and machine learning are accelerating research timelines, improving clinical trial efficiency, and enabling data-driven decision-making. Additionally, partnerships between tech companies and pharmaceutical firms are fostering cross-disciplinary breakthroughs. With a growing focus on unmet medical needs and value-based outcomes, the future of pharma innovation lies in smarter, faster, and more patient-centric solutions.
